Last reviewed · How we verify

NCT05970952: AKI-ICU

Acute Kidney Injury in Intensive Care Patients

Status unknown Last updated 2 August 2023
What this trial tests

trial in Acute Renal Injury in 159 participants. Status unknown.

Timeline
1 May 2023
Primary endpoint
24 October 2023
24 November 2023

Quick facts

Lead sponsorHaseki Training and Research Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment159
Start date1 May 2023
Primary completion24 October 2023
Estimated completion24 November 2023
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Haseki Training and Research Hospital

Who can join

Adults 18 to 100, any sex, with Acute Renal Injury or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective observational study is to evaluate the incidence, risk factors, and outcomes for development of acute kidney injury (AKI) in intensive care pateints. The main questions it aims to answer are: * What is the incidence of acute kidney injury in intensive care patients? * What are risk factors for development of acute kidney injury? All adult patients admitted to the ICU with a stay of 48 h or more will be included in the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Incidence, risk factors and outcome for acute kidney injury in the ICU: a prospective observational study
    Uzman S, Halici M, Çoban O, Yalim C, et al · · 2026 · DOI 10.21203/rs.3.rs-9071222/v1

Verify or expand the search:

Other recruiting trials for Acute Renal Injury

Currently open trials in the same condition.

Other Haseki Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05970952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing